

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Boyle

Serial No.: 09/211,297

Group Art Unit No.: 1644

Filed: December 14, 1998

Examiner: Szperka, Michael E.

For: Antibodies to Osteoprotegerin Binding
Proteins

Docket No.: A-451M

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR §§ 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified 1449 form and provide a copy of the listed references other than published U.S. patent applications and issued U.S. patents for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

Identification of the listed references is not to be construed as an Admission by Applicants or attorney for Applicants that such references are available or qualify as "prior art" against the subject application. Applicants reserve the right to remove any such reference which the Patent and Trademark Office may cite against the subject application.

This Information Disclosure Statement is being submitted in compliance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first office action after the filing of a request for continued examination under § 1.114. No fee should be due with respect to the filing of this information disclosure statement.

Applicants request consideration of this information and passage of the application to issue.

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

April 20, 2010

Date

/Nola J. Diamond/

Signature

FEE PAYMENT

No fee is due for submission of this information disclosure statement because it is filed along with a Request for Continued Examination in compliance with 37 C.F.R. § 1.97(b)(4).

The Commissioner is hereby authorized to charge any additional fee(s) which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34, 458
Phone: (805) 447-2425
Date: April 20, 2010

Please send all future correspondence to:
21069
U.S. Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799